Arvik Pharma Profile
Key Indicators
- Authorised Capital ₹ 1.00 Cr
as on 15-06-2024
- Paid Up Capital ₹ 2.10 M
as on 15-06-2024
- Company Age 6 Year, 6 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 1.90 M
as on 15-06-2024
- Revenue -76.18%
(FY 2023)
- Profit -185.39%
(FY 2023)
- Ebitda -210.21%
(FY 2023)
- Net Worth -6.09%
(FY 2023)
- Total Assets -6.23%
(FY 2023)
About Arvik Pharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 Cr and a paid-up capital of Rs 2.10 M.
The company currently has active open charges totaling ₹1.90 M.
Sai Mandalapu and Gangi Narravula serve as directors at the Company.
- CIN/LLPIN
U74999TG2018PTC125133
- Company No.
125133
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
15 Jun 2018
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Arvik Pharma Private Limited offer?
Arvik Pharma Private Limited offers a wide range of products and services, including Weighing Scales & Measuring Tapes, Precision Balance.
Who are the key members and board of directors at Arvik Pharma?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sai Mandalapu  | Director | 15-Jun-2018 | Current |
| Gangi Narravula | Director | 15-Jun-2018 | Current |
Financial Performance of Arvik Pharma.
Arvik Pharma Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 76.18% decrease. The company also saw a substantial fall in profitability, with a 185.39% decrease in profit. The company's net worth dipped by a decrease of 6.09%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Arvik Pharma?
In 2023, Arvik Pharma had a promoter holding of 100.00%. The company had 1 Subsidiary and 1 Associate company. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Arvik Minerals Private LimitedActive 4 years 4 monthsSai Mandalapu and Gangi Narravula are mutual person
- Arvik Labs Private LimitedActive 4 years 4 months
Sai Mandalapu and Gangi Narravula are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 24 Jun 2020 | ₹1.90 M | Open |
How Many Employees Work at Arvik Pharma?
Unlock and access historical data on people associated with Arvik Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Arvik Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Arvik Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
